Cargando…

Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects

BACKGROUND: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudiganti, Venkateshwarlu, Kodur, Raveendra Ramamurthy, Kodur, Sushma Raveendra, Halemane, Manjunath, Deep, Dheeraj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997756/
https://www.ncbi.nlm.nih.gov/pubmed/27558585
http://dx.doi.org/10.1186/s12944-016-0306-4
_version_ 1782449837442072576
author Kudiganti, Venkateshwarlu
Kodur, Raveendra Ramamurthy
Kodur, Sushma Raveendra
Halemane, Manjunath
Deep, Dheeraj Kumar
author_facet Kudiganti, Venkateshwarlu
Kodur, Raveendra Ramamurthy
Kodur, Sushma Raveendra
Halemane, Manjunath
Deep, Dheeraj Kumar
author_sort Kudiganti, Venkateshwarlu
collection PubMed
description BACKGROUND: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy and tolerability of Meratrim in managing body weight in healthy overweight subjects. METHODS: Sixty participants with a mean BMI of 28.3 kg/m(2) were randomized into two groups receiving either 400 mg of Meratrim twice daily or two identical placebo capsules for a period of 16 weeks. Subjects were asked to consume about 2,000 kcal/day throughout the study period and walk 5 days a week for 30 min daily. The primary endpoint was defined as the change in body weight from baseline to end of week 16 for the Meratrim group versus placebo. Fifty seven subjects completed the trial. RESULTS: At study conclusion, statistically significant reductions in body weight (5.09 vs. 1.1 kg; p < 0.0001), BMI (1.91 vs. 0.43 kg/m(2); p < 0.0001), waist (9.97 vs. 3.71 cm; p < 0.001) and hip size (10.38 vs. 5.11 cm; p < 0.0001) were observed in the Meratrim versus the placebo group. Additionally, a significant change in serum LDL (−14.79 vs. 6.25 mg/dL; p < 0.0001), triglycerides (−43.62 vs. -13.68 mg/dL; p < 0.001) and total cholesterol (−20.0 vs. -0.75 mg/dL; p = 0.0002) was observed in the Meratrim cohort compared to the placebo. No supplementation related adverse events were noted during the study. CONCLUSIONS: The study findings suggest that Meratrim is well-tolerated and is an effective ingredient for weight management in healthy overweight subjects. TRIAL REGISTRATION: CTRI/2014/07/004727; www.CTRI.nic.in
format Online
Article
Text
id pubmed-4997756
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49977562016-08-26 Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects Kudiganti, Venkateshwarlu Kodur, Raveendra Ramamurthy Kodur, Sushma Raveendra Halemane, Manjunath Deep, Dheeraj Kumar Lipids Health Dis Research BACKGROUND: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy and tolerability of Meratrim in managing body weight in healthy overweight subjects. METHODS: Sixty participants with a mean BMI of 28.3 kg/m(2) were randomized into two groups receiving either 400 mg of Meratrim twice daily or two identical placebo capsules for a period of 16 weeks. Subjects were asked to consume about 2,000 kcal/day throughout the study period and walk 5 days a week for 30 min daily. The primary endpoint was defined as the change in body weight from baseline to end of week 16 for the Meratrim group versus placebo. Fifty seven subjects completed the trial. RESULTS: At study conclusion, statistically significant reductions in body weight (5.09 vs. 1.1 kg; p < 0.0001), BMI (1.91 vs. 0.43 kg/m(2); p < 0.0001), waist (9.97 vs. 3.71 cm; p < 0.001) and hip size (10.38 vs. 5.11 cm; p < 0.0001) were observed in the Meratrim versus the placebo group. Additionally, a significant change in serum LDL (−14.79 vs. 6.25 mg/dL; p < 0.0001), triglycerides (−43.62 vs. -13.68 mg/dL; p < 0.001) and total cholesterol (−20.0 vs. -0.75 mg/dL; p = 0.0002) was observed in the Meratrim cohort compared to the placebo. No supplementation related adverse events were noted during the study. CONCLUSIONS: The study findings suggest that Meratrim is well-tolerated and is an effective ingredient for weight management in healthy overweight subjects. TRIAL REGISTRATION: CTRI/2014/07/004727; www.CTRI.nic.in BioMed Central 2016-08-24 /pmc/articles/PMC4997756/ /pubmed/27558585 http://dx.doi.org/10.1186/s12944-016-0306-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kudiganti, Venkateshwarlu
Kodur, Raveendra Ramamurthy
Kodur, Sushma Raveendra
Halemane, Manjunath
Deep, Dheeraj Kumar
Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title_full Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title_fullStr Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title_full_unstemmed Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title_short Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
title_sort efficacy and tolerability of meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997756/
https://www.ncbi.nlm.nih.gov/pubmed/27558585
http://dx.doi.org/10.1186/s12944-016-0306-4
work_keys_str_mv AT kudigantivenkateshwarlu efficacyandtolerabilityofmeratrimforweightmanagementarandomizeddoubleblindplacebocontrolledstudyinhealthyoverweighthumansubjects
AT kodurraveendraramamurthy efficacyandtolerabilityofmeratrimforweightmanagementarandomizeddoubleblindplacebocontrolledstudyinhealthyoverweighthumansubjects
AT kodursushmaraveendra efficacyandtolerabilityofmeratrimforweightmanagementarandomizeddoubleblindplacebocontrolledstudyinhealthyoverweighthumansubjects
AT halemanemanjunath efficacyandtolerabilityofmeratrimforweightmanagementarandomizeddoubleblindplacebocontrolledstudyinhealthyoverweighthumansubjects
AT deepdheerajkumar efficacyandtolerabilityofmeratrimforweightmanagementarandomizeddoubleblindplacebocontrolledstudyinhealthyoverweighthumansubjects